Cost Value

ICER’s Asthma Report Comes up Short

October 22, 2018

It’s plagued by incomplete analysis and missing data, yet the Institute for Clinical and Economic Review’s draft evidence report on severe asthma medicine still manages to deliver a familiar refrain.  All five of the drugs reviewed, ICER reports, are not cost-effective.

Summer 2018: A Health Policy Recap in 10 Quotes

August 30, 2018

Patient access developments didn’t stop for summer.  As we head into fall, here are 10 quotes from the news items – and new materials – that kept the health policy conversation lively during summer 2018.

Patient Access Withers Under ICER’s Influence

August 28, 2018

CVS Health recently announced that employers who use its pharmacy benefit management services can cut certain medications from their plan’s formulary of approved drugs.  Which drugs? Those that exceed a cost-effectiveness threshold established by ICER, the Institute for Clinical and Economic Review.  

How ICER Gets it Wrong

August 9, 2018

An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.

The Importation Question

July 24, 2018

To import, or not to import?  The question of whether to bring foreign, lower-priced versions of prescription drugs to the United States is back.  

Final ICER Report Leaves Cystic Fibrosis Community Uneasy

June 8, 2018

Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report.  The drugs can “substantially improve patient health outcomes,” the group concedes, but their prices exceed ICER’s cost-effectiveness threshold. One manufacturer has called ICER’s analysis “a sham.”